Diversified Management Inc. Makes New $2.83 Million Investment in Becton, Dickinson and Company $BDX

Key Points

• Diversified Management Inc. acquired a new $2.83 million stake in Becton, Dickinson and Company during the third quarter, purchasing 15,813 shares. Institutional investors collectively own 86.97% of the company.
• BD reported quarterly EPS of $3.23, beating estimates of $3.14, while revenue rose 5.4% year over year to $4.98 billion. The company set fiscal 2026 EPS guidance at $12.62–$12.72.
• Shares opened at $182.54, near the analyst consensus target of $185.07, with a consensus “Hold” rating. BD also recently paid a quarterly dividend of $1.05 per share, equivalent to a 2.3% annualized yield.

Diversified Management Inc. acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 15,813 shares of the medical instruments supplier's stock, valued at approximately $2,831,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $26,000. Meeder Asset Management Inc. raised its position in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 102 shares during the period. Bayban purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $36,000. Main Street Group LTD acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $29,000. Finally, Bell Investment Advisors Inc purchased a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $29,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares of the company's stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 6,906 shares of company stock worth $1,265,855. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Up 1.3%

NYSE BDX opened at $182.54 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The business's fifty day simple moving average is $181.98 and its 200-day simple moving average is $162.38. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The firm has a market cap of $50.30 billion, a PE ratio of 54.98, a P/E/G ratio of 12.15 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the company earned $3.68 EPS. The business's revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is 126.51%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Barclays assumed coverage on shares of Becton, Dickinson and Company in a research note on Wednesday. They issued an "underweight" rating and a $165.00 price target on the stock. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Piper Sandler lifted their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Finally, Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of "Hold" and an average target price of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.